Opebacan

Drug Profile

Opebacan

Alternative Names: BPI 21; Neuprex; rBPI21; Recombinant bactericidal permeability increasing protein 21

Latest Information Update: 03 Aug 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator New York University
  • Developer XOMA
  • Class Antibacterials; Recombinant proteins
  • Mechanism of Action Angiogenesis inhibitors; Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Meningococcal infections

Highest Development Phases

  • No development reported Meningococcal infections; Postoperative infections; Radiation injuries; Wound infections
  • Discontinued Graft-versus-host disease; Post-traumatic infections

Most Recent Events

  • 03 Aug 2010 Discontinued - Phase-I/II for Graft-versus-host disease in USA (Parenteral)
  • 09 Jan 2007 Phase-I/II clinical trials in Graft-versus-host disease in USA (Parenteral)
  • 06 Sep 2006 Opebacan has received orphan drug status for Meningococcal infections in the European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top